Scotiabank Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Adaptive Biotechnologies (ADPT) and Rezolute (RZLT)
Scotiabank Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $7
Adaptive Biotechnologies Analyst Ratings
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $5
TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
Adaptive Biotechnologies (ADPT) Receives a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), Veracyte (VCYT) and Nevro Corp (NVRO)
Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)
BTIG Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Adaptive Biotechnologies (ADPT)
J.P. Morgan Sticks to Its Buy Rating for Adaptive Biotechnologies (ADPT)
BTIG Reaffirms Their Buy Rating on Adaptive Biotechnologies (ADPT)
Analysts' Top Healthcare Picks: RxSight (RXST), Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Analyst Ratings
Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies: Hold Rating Justified by Mixed Financial Results and Ongoing Strategic Review Uncertainty
No Data